Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments.
Business Segments:
Lupin is present in India through Lupin Life, Lupin Diagnostics, Life Atharv Ability, SciFlix, Humrahi, Pharmarack.
Sales Mix Q2FY24
India : 34%
US : 38%
API : 5%
EMEA : 10%
ROW : 4%
Growth markets : 9%
Shareholding Pattern (December 2025):
Financial Summary:
| Particular | Mar-21 | Mar-22 | Mar-23 | Mar-24 | Mar-25 |
| Sales – | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 |
| Sales Growth % | -1.38% | 8.19% | 1.44% | 20.25% | 13.48% |
| Expenses + | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 |
| Operating Profit | 2,567 | 219 | 1,721 | 3,800 | 5,278 |
| OPM % | 17% | 1% | 10% | 19% | 23% |
| Net Profit + | 1,228 | -1,528 | 448 | 1,936 | 3,306 |
| EPS in Rs | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 |
| Dividend Payout % | 24% | -12% | 42% | 19% | 17% |
Synopsis of Financials:
Q3 FY26: Financial performance:
Revenue from operations INR 7,168 cr (+24% YoY), with EBITDA margin 31.1% (+681 bps YoY).
Gross margin expanded further to 73.5% (vs 69.4% in Q3 FY25; +420 bps YoY)
Other operating income fell sharply to INR 67 cr (vs INR 149 cr in Q3 FY25; INR 216 cr in Q2 FY26)
Final Outlook:
Simple Summary:
Lupin has shown a strong recovery after a weak phase, with improving revenue, margins, and profitability. Growth is supported by better performance in the US market, strong domestic business, and focus on high-margin specialty products. The company has also reduced its debt and improved operational efficiency. However, the pharmaceutical industry remains competitive and subject to regulatory risks, especially in the US. Overall, Lupin is moving back into a stable growth phase.
Recent Performance (Q3 FY26 – Easy View)
- Revenue growth: ~+11% YoY
- EBITDA margin improving due to cost control
- Strong performance in US and India markets
- Focus on complex generics and specialty drugs
Simple Understanding
- Revenue is growing steadily again after slowdown
- Profit dropped earlier but strong recovery in FY24–FY25
- Margins are improving again (good sign)
- Debt is gradually reducing
Final Verdict: HOLD
Lupin is a recovering pharma company with improving financial performance and better growth visibility. However, due to industry competition and regulatory risks, near-term upside may be moderate.
